The epidemiology of Shiga toxin-producing

Escherichia coli foodborne zoonoses gastrointestinal infections infectious disease epidemiology zoonotic foodborne diseases

Journal

Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737

Informations de publication

Date de publication:
11 02 2022
Historique:
entrez: 4 3 2022
pubmed: 5 3 2022
medline: 23 4 2022
Statut: epublish

Résumé

Shiga toxin-producing Escherichia coli (STEC) serogroup O157 is a zoonotic, foodborne gastrointestinal pathogen of major public health concern. We describe the epidemiology of STEC O157 infection in England by exploring the microbiological and clinical characteristics, the demographic and geographical distribution of cases, and examining changes in environmental exposures over 11 years of enhanced surveillance. Enhanced surveillance data including microbiological subtyping, clinical presentations and exposures were extracted for all cases resident in England with evidence of STEC O157 infection, either due to faecal culture or serology detection. Incidence rates were calculated based on mid-year population estimates from the Office of National Statistics (ONS). Demographics, geography, severity and environmental exposures were compared across the time periods 2009-2014 and 2015-2019. The number of cases reported to national surveillance decreased, with the mean cases per year dropping from 887 for the period 2009-2014 to 595 for the period 2015-2019. The decline in STEC O157 infections appears to be mirrored by the decrease in cases infected with phage type 21/28. Although the percentage of cases that developed HUS decreased, the percentage of cases reporting bloody diarrhoea and hospitalisation remained stable. The number of outbreaks declined over time, although more refined typing methods linked more cases to each outbreak. Integration of epidemiological data with microbiological typing data is essential to understanding the changes in the burden of STEC infection, assessment of the risks to public health, and the prediction and mitigation of emerging threats.

Identifiants

pubmed: 35241189
doi: 10.1017/S0950268822000206
pii: S0950268822000206
pmc: PMC8915195
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e52

Subventions

Organisme : Department of Health
Pays : United Kingdom

Références

Clin Infect Dis. 2015 Aug 1;61(3):305-12
pubmed: 25888672
IARC Sci Publ. 1987;(82):1-406
pubmed: 3329634
Emerg Infect Dis. 2020 Oct;26(10):2394-2400
pubmed: 32946720
J Appl Microbiol. 1999 May;86(5):731-40
pubmed: 10347867
Epidemiol Infect. 2017 Nov;145(15):3168-3179
pubmed: 28925340
Microb Genom. 2020 Mar;6(3):
pubmed: 32100710
Emerg Infect Dis. 2016 Apr;22(4):590-7
pubmed: 26982243
J Med Microbiol. 2012 Aug;61(Pt 8):1082-1085
pubmed: 22516135
J Med Microbiol. 2021 Jul;70(7):
pubmed: 34309502
Microb Genom. 2015 Sep 14;1(3):e000029
pubmed: 28348814
Epidemiol Infect. 2021 May 06;149:e124
pubmed: 33955833
Emerg Infect Dis. 2005 Apr;11(4):590-6
pubmed: 15829199
Epidemiol Infect. 2019 Jan;147:e215
pubmed: 31364538
BMJ Open. 2016 Jan 29;6(1):e009933
pubmed: 26826153
Emerg Infect Dis. 2018 Dec;24(12):2303-2308
pubmed: 30457532
Epidemiol Infect. 2020 Jul 16;148:e215
pubmed: 32669142
Microb Genom. 2018 Mar;4(3):
pubmed: 29488865
Epidemiol Infect. 2018 Nov;146(15):1928-1939
pubmed: 30205851
Euro Surveill. 2019 Apr;24(16):
pubmed: 31014418
Epidemiol Infect. 2015 Dec;143(16):3475-87
pubmed: 25920912
Epidemiol Infect. 1989 Aug;103(1):73-81
pubmed: 2673827
BMJ Open. 2016 Sep 13;6(9):e011119
pubmed: 27625054

Auteurs

Saira Butt (S)

National Infection Service, Public Health England, London, UK.

Claire Jenkins (C)

National Infection Service, Public Health England, London, UK.

Gauri Godbole (G)

National Infection Service, Public Health England, London, UK.

Lisa Byrne (L)

National Infection Service, Public Health England, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH